# The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke

Study · id `cardio:ct-nct01364220` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01364220](<https://clinicaltrials.gov/study/NCT01364220>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01364220

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 318 participants.

## Technical summary

Registry record NCT01364220. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2013-04 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 318 participants (enrolled count; ClinicalTrials.gov record NCT01364220, source copy `cardio:ctgov-nct01364220-2014-11-20`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01364220, source copy `cardio:ctgov-nct01364220-2014-11-20`, retrieved 2026-10-26)
- Primary completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01364220, source copy `cardio:ctgov-nct01364220-2014-11-20`, retrieved 2026-10-26)
- Completion: 2013-04 (actual) (ClinicalTrials.gov record NCT01364220, source copy `cardio:ctgov-nct01364220-2014-11-20`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01364220, source copy `cardio:ctgov-nct01364220-2014-11-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01364220-2014-11-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Effects of Very Early Use of Rosuvastatin in Preventing Recurrence of Ischemic Stroke
- Acronym: EUREKA
- Condition: Stroke
- Intervention (Drug): Rosuvastatin
- Intervention (Other): Placebo tablet
- Lead sponsor: Severance Hospital
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)
- Registry lists this organization as the lead sponsor: Severance Hospital (`cardio:org-severance-hospital`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 50a9b07615cb0215dba793db61dadec8865814bced952b3850eaf7b5088fa7bd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
